Inloggad som:

MK-6482-015

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

MK-6482-015
A Phase 2 Study to Evaluate the Effficacy and Safety of Belzutifan (formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
PLACEHOLDER
A Phase 2 Study to Evaluate the Effficacy and Safety of Belzutifan (formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)
Mer information om studien för vårdgivare
För patienter med Neuroendokrin pancreascancer
Kan inte svälja oralt läkemedel eller har en störning som kan påverka absorptionen av belzutifan
Behandling
Fas 2
Palliativ
Företag

Studien ändrades senast av: Susanne Zachau (2023-10-18)

Tillbaka till listan